Canadian health regulators approve InterMune’s fibrosis drug
(Reuters) – Biotechnology company InterMune Inc said Canadian health regulators approved its drug to treat idiopathic pulmonary fibrosis, a fatal lung disease. InterMune expects the drug Esbriet, chemically known as pirfenidone, to be available for sale in Canada from January 1, 2013. The company said it expects to secure reimbursement for the drug from most private insurance plans by the third quarter of 2013, adding that reimbursements from public plans are typically secured within six to 18 months of a launch. …